What is Pulmonx?
Pulmonx Corporation is at the forefront of developing and commercializing innovative treatments for severe emphysema, a debilitating form of COPD. Its flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to alleviate breathing difficulties by reducing lung hyperinflation. Complementing this are diagnostic and planning tools like the Chartis® Pulmonary Assessment System and StratX®/LungTraX® platforms, which leverage advanced imaging to identify suitable candidates for treatment. Having treated over 40,000 patients globally, Pulmonx has established itself as a leader in the interventional pulmonology sector, offering a lifeline to individuals suffering from chronic respiratory conditions.
How much funding has Pulmonx raised?
Pulmonx has raised a total of $421.1M across 10 funding rounds:
Series A
$7.1M
Series B
$20M
Series C
$32M
Series D
$10M
Private Equity
$10M
Debt
$20M
Private Equity
$50M
Multiple Rounds
$272M
Series A (2003): $7.1M with participation from Montreux Equity Partners and MedVenture Associates
Series B (2007): $20M led by MedVenture Associates, Montreux Equity Partners, Latterell Venture Partners, and DeNovo Ventures
Series C (2010): $32M supported by Latterell Venture Partners, Healthcap Venture Capital, Montreux Equity Partners, De Novo Ventures, Kleiner Perkins Caufield & Byers, and MedVenture Associates
Series D (2012): $10M, investors not publicly disclosed
Private Equity (2014): $10M, investors not publicly disclosed
Debt (2014): $20M with participation from Oxford Finance, LLC
Private Equity (2015): $50M, investors not publicly disclosed
Debt (2020): $65M supported by Ally Bridge Group, Partner Fund Management , L.P., Rock Springs Capital LLC, HealthQuest Capital, and ADAGE CAPITAL MANAGEMENT LP
Debt (2020): $17M featuring CIBC
Stock Issuance/Offering (2020): $190M, investors not publicly disclosed
Key Investors in Pulmonx
MedVenture Associates
MedVenture Associates is a venture capital firm specializing in the design, development, and manufacturing of minimally invasive catheter-based devices, focusing on integrated solutions for various medical markets.
Montreux Equity Partners
Montreux Equity Partners focuses on investing in high-growth, commercial-stage companies, aiming to accelerate their scale and drive expansion through strategic growth investments.
Latterell Venture Partners
Latterell Venture Partners is a venture capital firm that invests in early-stage healthcare companies, particularly in biotechnology and medical devices, providing capital and expertise to foster innovation.
What's next for Pulmonx?
The recent major strategic investment signals a new phase of growth and development for Pulmonx. This capital infusion is expected to accelerate the company's commercial expansion, further research and development into its minimally invasive treatment portfolio, and potentially broaden its market reach. With a strong foundation in treating severe emphysema, Pulmonx is well-positioned to continue its trajectory as a key innovator in respiratory care, aiming to improve the quality of life for a growing number of patients worldwide.
See full Pulmonx company page
